|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent findings convincingly support the concept of a new function of the VDR as a tumor suppressor in skin, with key components of the vitamin D endocrine system, including VDR, CYP24A1, CYP27A1, and CYP27B1 being strongly expressed in non-melanoma skin cancer (NMSC).
|
28526240 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ethanol intake decreased renal Cyp27b1 while increased tumoral CYP24A1 gene expression.Treatment with 25-hydroxyvitamin D<sub>3</sub> significantly stimulated CYP27B1 in tumors of non-alcohol-drinking mice, while increased both renal and tumoral CYP24A1.
|
27639478 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results demonstrated that the mRNA expression of CYP27B1 was downregulated in the tumor tissues, compared with the adjacent normal tissues (P<0.01), whereas the mRNA expression of CYP24A1 was significantly upregulated in the tumor tissues (P<0.01).
|
27922682 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CYP27B1 and CYP24A1 expression were significantly different between tumor and normal tissues in NSCLC.
|
25544771 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, CYP27B1 expression was negatively correlated with tumor cell modeling of their microenvironment.
|
25501638 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The study reveals active CYP1 overexpression in human tumors and uncovers the potential use of CYP1 enzymes and mainly CYP1B1 as targets for cancer therapy.
|
24358191 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunoreactivity for CYP27B1 was significantly lower in the vertical growth phase and metastatic melanomas (0.6 and 0.5 arbitrary units, respectively) in comparison with nevi and radial growth phase tumors (1.2 and 1.1 arbitrary units, respectively); and expression was reduced in more advanced lesions (Clark levels III-V, Breslow thickness ≥2.1 mm; 0.8 and 0.7 arbitrary units, respectively).
|
22995334 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The vitamin D(3) diet raised circulating 1,25 dihydroxyvitamin D levels and did not alter CYP27B1 mRNA in the kidney but increased it in the tumors, suggesting that extrarenal sources including the tumors contributed to the elevated circulating 1,25 dihydroxyvitamin D(3).
|
22454149 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, emerging evidence suggests that deregulation of VDR and CYP27B1 occurs during cancer development and contributes to abrogation of the tumor suppressive effects triggered by 25D.
|
21669251 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings indicate that CYP27B1 does not commonly serve as a classical tumor suppressor gene in the development of sporadic parathyroid adenomas or of refractory secondary/tertiary hyperparathyroidism.
|
18767934 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate.
|
18649741 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression analysis of CYP27B1 in tumor biopsies and cell cultures.
|
16886678 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, prostate cancer cells, both primary cultured cells and cell lines, have greatly decreased activity of 1alpha(OH)ase and are therefore resistant to the tumor suppressor activity of circulating 25(OH)D(3).
|
15223133 |
2004 |